- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04009512
Endovascular Repair of Thoracoabdominal Aortic Aneurysms
Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Primary Arm Inclusion Criteria:
A patient may be entered into the study if the patient has at least one of the following:
- An aneurysm with a maximum diameter of > 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
- Aneurysm with a history of growth > 0.5 cm in 6 months
- Saccular aneurysm deemed at significant risk for rupture
- Symptomatic aneurysm greater than or equal to 4.5 cm
Other inclusion criteria
- Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
Proximal landing zone for the thoracic bifurcation stent graft that has:
- ≥ 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA) and a diameter in the range of 26-42 mm
- Adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold
- Iliac artery or aortic distal fixation site, including both native tissue and previously placed graft, greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm
- Age: ≥ 18 years old
- Life expectancy: > 1 year
Exclusion Criteria:
Primary Arm Exclusion criteria
- Patient is a good candidate for and elects for open surgical repair
- Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis
- Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
- Unwilling to comply with the follow-up schedule
- Inability or refusal to give informed consent by patient or legal representative
- Urgent or emergent presentation
- Patient is pregnant or breastfeeding
- Patient has a contained rupture
- Patient has a ruptured aneurysm
- Patient has a dissection in the portion of the aorta intended to be treated
- Obstructive stenting of any or all of the visceral vessels
- Poor performance status including two major system failures (including but not limited to cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular)
Medical exclusion criteria
- Known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel: Titanium), polyester, platinum-iridium, polytetrafluoroethylene (PTFE), platinum, gold, polyethylene, or stainless steel.
- Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
- Uncorrectable coagulopathy
- Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
- Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair
- Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
- Systemic or local infection that may increase the risk of endovascular graft infection
- Baseline creatinine greater than or equal to 2.0 mg/dL
- History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
- Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in a landing zone that expands beyond any limits of the previously placed graft material
Anatomical exclusion criteria
- Minimum branch vessel diameter less than 5 mm
- Thrombus or excessive calcification within the proximal aortic neck
- Anatomy that would not allow maintenance of at least one patent hypogastric artery
- Anatomy that would not allow primary or assisted patency of the left subclavian artery
Expanded Use Arm Inclusion Criteria
Patient that meet the criteria for inclusion in the primary study arm but has one or more of the following criteria which would exclude them from the primary study arm:
An expanded use arm of the study will broaden inclusion criteria to include patients with the following :
- Minimum branch vessel diameter <5mm
- Urgent or emergent presentation
- Patient has a contained rupture
- Patient has a ruptured aneurysm
- Patient has a type B dissection (subacute or chronic) in the portion of the aorta intended to be treated
- Poor performance status including two major system failures (including but not limited to cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular)
- Baseline creatinine greater than or equal to 2.0 mg/dL
- Anatomy that does not allow maintenance of at least one hypogastric artery
- Anatomy that does not allow primary or assisted patency of the left subclavian artery
- Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in a landing zone that expands beyond any limits of the previously placed graft material
- Obstructive stenting of any or all of the visceral vessels
Patient that meets the criteria for inclusion in the primary study arm and:
- Would not be eligible for the primary study arm per a documented reason other than those outlined above, and
- Per the opinion of the Principal Investigator, with concurrence of the IRB, alternative therapies are unsatisfactory and the probable risk of using the investigational device is no greater than the probable risk from the disease or condition.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Primary Study Arm
The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold.
These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
|
This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
|
Experimental: Expanded Use Arm
The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold.
These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
|
This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from MAEs (at 30 Days)
Time Frame: 30 Days post- procedure
|
Major Adverse Events include: all-cause mortality within 30 days of the procedure, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, and stroke.
|
30 Days post- procedure
|
Preliminary Effectiveness (treatment and technical success)
Time Frame: 1- year post-procedure
|
Treatment success is defined as a composite of technical success and freedom from the following:
|
1- year post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: at each follow-up interval (five years)
|
Technical success and the individual components of technical success include:
|
at each follow-up interval (five years)
|
Treatment Success
Time Frame: at each follow-up interval (five years)
|
Treatment success and the individual components of treatment success including freedom from the following at each follow-up interval:
|
at each follow-up interval (five years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IP-01-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracoabdominal Aortic Aneurysm
-
The Christ HospitalMedtronicRecruiting
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingThoracoabdominal Aortic AneurysmsChina
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Assiut UniversityNot yet recruitingThoracoabdominal Aortic Aneurysm
-
JOTEC GmbHRecruitingThoracoabdominal Aortic AneurysmNew Zealand, Thailand, Australia
-
W.L.Gore & AssociatesCompletedThoracoabdominal Aortic AneurysmUnited States
-
Uppsala UniversityNot yet recruitingThoracoabdominal Aortic Aneurysm
-
JOTEC GmbHRecruiting
-
Dr. Sabrina OverhagenBentley InnoMed GmbHActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of RuptureGermany
Clinical Trials on Valiant Thoracoabdominal Stent Graft System
-
The Christ HospitalMedtronicRecruiting
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States, United Kingdom
-
Medtronic CardiovascularNAMSAActive, not recruitingThoracic Aortic DissectionUnited States, Korea, Republic of, Netherlands, Denmark, New Zealand, Thailand, Japan, Slovakia, Greece, Italy
-
Medtronic CardiovascularCompletedAortic Aneurysm, ThoracicNetherlands, Denmark, United Kingdom, France, Canada, Italy
-
Medtronic CardiovascularTerminatedAortic Aneurysm, ThoracicGermany, United Kingdom, Netherlands, Turkey, Austria, Spain, Italy
-
Arizona Heart InstituteUnknownThoracic Aortic AneurysmUnited States
-
Medtronic CardiovascularCompleted
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingThoracoabdominal Aortic AneurysmsChina